En busqueda del hipnótico ideal: tratamiento farmacológico del insomnio
El insomnio es un trastorno del sueño caracterizado por dificultad para la conciliación o mantenimiento del sueño, por disminución del tiempo, fragmentación o mala calidad del sueño, y sensación de cansancio al día siguiente. Se trata de un problema con gran prevalencia en países industrializados y...
- Autores:
-
Chávez, Mervin
Nava, Manuel
Palmar, Jim
Martínez, María Sofía
Graterol Rivas, Modesto
Contreras, Julio
Hernández, Juan Diego
Bermúdez, Valmore
- Tipo de recurso:
- Fecha de publicación:
- 2017
- Institución:
- Universidad Simón Bolívar
- Repositorio:
- Repositorio Digital USB
- Idioma:
- spa
- OAI Identifier:
- oai:bonga.unisimon.edu.co:20.500.12442/1916
- Acceso en línea:
- http://hdl.handle.net/20.500.12442/1916
- Palabra clave:
- Insomnio
Hipnótico ideal
Arquitectura del sueño
Drogas Z
Benzodiacepinas
Insomnia
Ideal hypnotic
Sleep architecture
Z drugs,
Benzodiazepines
- Rights
- License
- Licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional
| id |
USIMONBOL2_acc94741c746d3f320a356309dccac37 |
|---|---|
| oai_identifier_str |
oai:bonga.unisimon.edu.co:20.500.12442/1916 |
| network_acronym_str |
USIMONBOL2 |
| network_name_str |
Repositorio Digital USB |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
En busqueda del hipnótico ideal: tratamiento farmacológico del insomnio |
| dc.title.alternative.eng.fl_str_mv |
Searching for the ideal hypnotic: pharmacological treatment of insomnia |
| title |
En busqueda del hipnótico ideal: tratamiento farmacológico del insomnio |
| spellingShingle |
En busqueda del hipnótico ideal: tratamiento farmacológico del insomnio Insomnio Hipnótico ideal Arquitectura del sueño Drogas Z Benzodiacepinas Insomnia Ideal hypnotic Sleep architecture Z drugs, Benzodiazepines |
| title_short |
En busqueda del hipnótico ideal: tratamiento farmacológico del insomnio |
| title_full |
En busqueda del hipnótico ideal: tratamiento farmacológico del insomnio |
| title_fullStr |
En busqueda del hipnótico ideal: tratamiento farmacológico del insomnio |
| title_full_unstemmed |
En busqueda del hipnótico ideal: tratamiento farmacológico del insomnio |
| title_sort |
En busqueda del hipnótico ideal: tratamiento farmacológico del insomnio |
| dc.creator.fl_str_mv |
Chávez, Mervin Nava, Manuel Palmar, Jim Martínez, María Sofía Graterol Rivas, Modesto Contreras, Julio Hernández, Juan Diego Bermúdez, Valmore |
| dc.contributor.author.none.fl_str_mv |
Chávez, Mervin Nava, Manuel Palmar, Jim Martínez, María Sofía Graterol Rivas, Modesto Contreras, Julio Hernández, Juan Diego Bermúdez, Valmore |
| dc.subject.spa.fl_str_mv |
Insomnio Hipnótico ideal Arquitectura del sueño Drogas Z Benzodiacepinas |
| topic |
Insomnio Hipnótico ideal Arquitectura del sueño Drogas Z Benzodiacepinas Insomnia Ideal hypnotic Sleep architecture Z drugs, Benzodiazepines |
| dc.subject.eng.fl_str_mv |
Insomnia Ideal hypnotic Sleep architecture Z drugs, Benzodiazepines |
| description |
El insomnio es un trastorno del sueño caracterizado por dificultad para la conciliación o mantenimiento del sueño, por disminución del tiempo, fragmentación o mala calidad del sueño, y sensación de cansancio al día siguiente. Se trata de un problema con gran prevalencia en países industrializados y representa uno de los motivos de consulta más frecuente en atención primaria. Su terapéutica incluye medidas farmacológicas y no farmacológicas. Las drogas hipnóticas incluyen un amplio rango de moléculas, como benzodiacepinas, compuestos Z, antidepresivos, antihistamínicos, entre otros, cada una con propiedades farmacodinámicas y farmacocinéticas particulares. Basada en evidencia clínica-epidemiológica, esta revisión discute la eficacia y seguridad de los fármacos hipnóticos, con el objetivo de establecer el prototipo de hipnótico ideal para cada tipo de insomnio, considerando las necesidades o condiciones del paciente. |
| publishDate |
2017 |
| dc.date.issued.none.fl_str_mv |
2017 |
| dc.date.accessioned.none.fl_str_mv |
2018-03-23T15:25:39Z |
| dc.date.available.none.fl_str_mv |
2018-03-23T15:25:39Z |
| dc.type.spa.fl_str_mv |
article |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
| dc.identifier.issn.none.fl_str_mv |
26107988 |
| dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/20.500.12442/1916 |
| identifier_str_mv |
26107988 |
| url |
http://hdl.handle.net/20.500.12442/1916 |
| dc.language.iso.spa.fl_str_mv |
spa |
| language |
spa |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.license.spa.fl_str_mv |
Licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional |
| rights_invalid_str_mv |
Licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional http://purl.org/coar/access_right/c_abf2 |
| dc.publisher.spa.fl_str_mv |
Sociedad Venezolana de Farmacología Clínica y Terapéutica |
| dc.source.spa.fl_str_mv |
AVFT-Archivos Venezolanos de Farmacología y Terapéutica Vol. 36, No.1 (2017) |
| institution |
Universidad Simón Bolívar |
| dc.source.uri.none.fl_str_mv |
http://www.revistaavft.com/images/revistas/2017/AVFT%201%202017/en%20busqueda%20del%20hipnotico%20ideal.pdf |
| bitstream.url.fl_str_mv |
https://bonga.unisimon.edu.co/bitstreams/9aac430c-2045-4e17-bd12-2384ac7185da/download |
| bitstream.checksum.fl_str_mv |
3fdc7b41651299350522650338f5754d |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 |
| repository.name.fl_str_mv |
Repositorio Digital Universidad Simón Bolívar |
| repository.mail.fl_str_mv |
repositorio.digital@unisimon.edu.co |
| _version_ |
1812100502359375872 |
| spelling |
Licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacionalhttp://purl.org/coar/access_right/c_abf2Chávez, Mervinfacd40d6-d5c6-4f0c-97cc-fef0c821e4c6Nava, Manuelcf0ca570-5fc3-4ec7-9913-90be952261e2Palmar, Jim28ef000c-350b-4805-8bca-b85e40db0d66Martínez, María Sofía24132de7-a45a-499c-aa91-9dc68c5cbf09Graterol Rivas, Modestoef8624a6-37dc-483c-9dc7-c2bbbe5ffd4aContreras, Julioee6833d4-08fc-4f10-8638-cd5206d5aeddHernández, Juan Diegod2e3538d-158e-424a-a3d4-37f5b19a238cBermúdez, Valmore29f9aa18-16a4-4fd3-8ce5-ed94a0b8663a2018-03-23T15:25:39Z2018-03-23T15:25:39Z201726107988http://hdl.handle.net/20.500.12442/1916El insomnio es un trastorno del sueño caracterizado por dificultad para la conciliación o mantenimiento del sueño, por disminución del tiempo, fragmentación o mala calidad del sueño, y sensación de cansancio al día siguiente. Se trata de un problema con gran prevalencia en países industrializados y representa uno de los motivos de consulta más frecuente en atención primaria. Su terapéutica incluye medidas farmacológicas y no farmacológicas. Las drogas hipnóticas incluyen un amplio rango de moléculas, como benzodiacepinas, compuestos Z, antidepresivos, antihistamínicos, entre otros, cada una con propiedades farmacodinámicas y farmacocinéticas particulares. Basada en evidencia clínica-epidemiológica, esta revisión discute la eficacia y seguridad de los fármacos hipnóticos, con el objetivo de establecer el prototipo de hipnótico ideal para cada tipo de insomnio, considerando las necesidades o condiciones del paciente.Insomnia is a sleep disorder characterized by difficulty for the onset or maintenance of sleep, as well as shortening, fragmentation or bad quality of sleep, and feeling unrested the following day. Insomnia boasts a high prevalence in industrialized countries, and represents one of the most frequent chief complaints in primary care. Treatment involves pharmacologic and non-pharmacologic measures. Hypnotic drugs include a wide range of molecules, such as benzodiazepines, z compounds, antidepressants, antihistamines and several others, each with distinct pharmacodynamic and pharmacokinetic properties. Based on clinical and epidemiologic evidence, this review discusses the efficacy and safety of hypnotic drugs, with the objective of establishing the prototype of the ideal hypnotic for each type of insomnia, according to the specific needs of each kind of patient.spaSociedad Venezolana de Farmacología Clínica y TerapéuticaAVFT-Archivos Venezolanos de Farmacología y TerapéuticaVol. 36, No.1 (2017)http://www.revistaavft.com/images/revistas/2017/AVFT%201%202017/en%20busqueda%20del%20hipnotico%20ideal.pdfInsomnioHipnótico idealArquitectura del sueñoDrogas ZBenzodiacepinasInsomniaIdeal hypnoticSleep architectureZ drugs,BenzodiazepinesEn busqueda del hipnótico ideal: tratamiento farmacológico del insomnioSearching for the ideal hypnotic: pharmacological treatment of insomniaarticlehttp://purl.org/coar/resource_type/c_6501American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5.a ed. Washington: American Psychiatric Association; 2013.State of the Sciencie Conference Statetment NIH. On manifestations and management of chronic insomnia in adults. NIH Consens State Sci Statements. 2005; 22:1-30.Morin Charles M., Denise C. Jarrin. Epidemiology of Insomnia Prevalence, Course, Risk Factors, and Public Health Burden. Sleep Med Clin. 2013; 8:281–297Ka-Fai C, Wing-Fai Y, Fiona Yan-Yee H, Kam-Ping Y, Yee-Man Y, Chi-Wa K. Cross-cultural and comparative epidemiology of insomnia: the Diagnostic and Statistical Manual (DSM), International Classification of Diseases (ICD) and International Classification of Sleep Disorders (ICSD). Sleep Medicine 16 (2015) 477–482Ohayon M. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002;6:97–111.Menezes AM, Perez-Padilla R, Jardim JR, et al. Chronic obstructive pulmonary disease in five Latin Americancities (the PLATINO study): a prevalence study. Lancet. 2005;366:1875-1881.Kryger, M. History of sleep medicine and physiology. In: Kruger M, Avidan A. Berry R. Atlas of Clinical Sleep Medicine: Expert Consult-Online. 2 ed. Elsevier Health Sciences; 2013. p. 8-19Mosby’s medical, nursing, and allied health dictionary. 9th ed. St. Louis: Mosby; 2011. Hipnótico; p. 706.Sourkes TL. Early clinical neurochemistry of CNS-active drugs. Chloral hydrate. Mol Chem Neurophath 1992;17:21-30.Balme R. Early medicinal uses of bromides. J R Coll Phys 1976;10:205-8.Willis G, Arendt E. Relative efficacy of sodium amytal, chloral hydrate and dichloralphenazone. Canad. M. A. J. 1954;71:126-128.Doghramji PP. Trends in the pharmacological management of insomnia. J Clin Psychiatry. 2006;67( 13):5-8Ebert B, Wafford KA, Deacon S. Treating insomnia: current and investigational parmacological approaches. Pharmaco Ther. 2006;112(3):612-629.Harrison N. Mechanisms of sleep induction by GABAA receptor agonists. J Clin Psychiatry. 2007; 68(suppl 5):6-12Siriwardena AN, Qureshi MZ, Dyas JV, Middleton H, Orner R. Magic bullets for insomnia? Patients’ use and experiences of newer (Z drugs) versus older (benzodiazepine) hypnotics for sleep problems in primary care. Br J Gen Pract 2008; 58: 417–422.M. Singh, CL Drake. Insomnio comorbido con condiciones medicas. Assessment, Methodology, Training, and Policies of Sleep. Encyclopedia of Sleep.2013:1;236-238.Wickboldt AT, Bowca AF, Kaye AI, Kaye AM, Rivera F, Kaye AD. Sleep physiology, abnormal states and therapeutic interventions. The Ochsner Journal . 2012; 12(2): 122-134.Colten H, Altevogt B (2006) Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem. Institute of Medicine (US) Committee on Sleep Medicine and Research. Washington (DC): National Academies Press (US).American Academy of Sleep Medicine. The AASM manual 2007 for the scoring of sleep and associated events rules, terminology and technical specifications. Westchester, IL. American Academy of Sleep Medicine; 2007Reynolds C, Taska L, Sewitch D, Restifo K, Coble P, Kupfer D. Persistent psychophysiologic insomnia: Preliminary research diagnostic criteria and EEG sleep data. Am J Psychiurry. 1984; 141(6):804-805.Hudson J, Pope H, Sullivan L, Waternaux C, Keck P, Broughton R. Good Sleep, ad Sleep: A Meta-Analysis of Polysomnographic Measures in Insomnia, Depression, and Narcolepsy. BIOL PSYCHIATRY. 1992;32:958-975.Hoffmann R, Paterok B, Müller T, Becker-Carus C. Patients of an ambulatory sleep center--critical variables of insomniacs. Wien Med Wochenschr. 1995;145(17-18):478-80.Rius R, Gironella D. Tratamiento Farmacológico del Insomnio. Butlletí d’informació terapèutica del Departament de Salut de la Generalitat de Catalunya. 2009; 21(2): 7-12.Tariq S. Pulisetty S. Pharmacotherapy for insomnia. Clin Geriartr med. 2008; 24: 93-105.Sanger D. The Pharmacology and Mechanisms of Action of New Generation, Non-Benzodiazepine Hypnotic Agents. CNS Drugs. 2004; 18 (1): 9–15.Diaz MA, Pareja J. Tratamiento del insomnio. Inf Ter Sist Nac Salud. 2008; 32(4): 116-122.Gunja N. The Clinical and Forensic Toxicology of Z-drugs. J. Med. Toxicol. 2013; 9(2):155-162.Verster JC, Veldhuijzen DS, Volkerts ER (2004) Residual effects of sleep medication on driving ability. Sleep Med Rev 8(4)309–325.Preskorn SH. A way of conceptualizing benzodiazepins to guide. Journal of Psychiatric Practice. 2015; 21(6):436-441.Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ. 2000;162(2):225–33.Rienmann D, Perliz M. The treatments of chronic insomnia: A review of benzodiazepine receptor agonists and psychological and behavioral therapies. Sleep Medicine Reviews. 2009; 13: 205–214Peng T, Patchett N, Bernard S. Takotsubo Cardiomyopathy and Catatonia in the Setting of Benzodiazepine Withdrawal. Case Reports in Cardiology. Volume 2016, Article ID 8153487, 3 pages. dx.doi.org/10.1155/2016/8153487.Hausken A, Furu K, Skurtveit S, Engeland A, Bramness J. Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors. Eur J Clin Pharmacol (2009) 65:295–301.Quera-Salva M, McCann C, Boudet J, Frisk M, Borderies P, Meyer P. Effects of zolpidem on sleep architecture, night time ventilation, daytime vigilance and performance in heavy snorers. Br J clin Pharmac 1994; 37: 539-543.Cirignotta F, Mondini S, Zucconi M, Gerardi R, Farolfi A, Lugaresi E. Zolpidempolysomnographic study of the effect of a new hypnotic drug in sleep apnea syndrome. Pharmac Biochem Behav 1988; 29: 807-809.Mahoney JE,WebbMJ,Gray SL. Zolpidem prescribing and adverse drug reactions in hospitalized general medicine patients at a Veterans Affairs hospital. Am J Geriatr Pharmacother 2004; 2(1): 66-74.Hoffmann F. Benefits and risks of benzodiazepines and Z-drugs: comparison of perceptions of GPs and community pharmacists in Germany. GMS Ger Med Sci. 2013;11:Doc10. DOI: 10.3205/000178, URN: urn:nbn:de:0183-0001780.Kripke DF.Greater incidence of depression with hypnotic use than with placebo. BMC Psychiatry 2007; 7: 42.Qaseem A, Kansagara D, Forciea M, Cooke M, Denberg T. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016;165(2):1-9. doi:10.7326/ M15-2175.Pompeia S, Lucchesi LM, Bueno OF, et al. Zolpidem and memory: a study using the process-dissociation procedure. Psychopharmacology (Berl). 2004; 174(3): 327–333.Goa KL, Heel RC (1986) Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs 32:48–65.Gursky J, Krahn L. The Effects of Antidepressants on Sleep: A Review. Harvard Rev Psychiatry. 2000; 8(6): 298-306.Holshoe J. Antidepressants and Sleep: A Review. Perspectives in Psychiatric Care 2009; 45(3): 191-197.Winokur A, Gary K, Rodner S, Rae-Red C, Fernando A, Szuba M. Depression, Sleep Physiology, and Antidepressant Drugs. Depression and Anxiety. 2001; 14:19–28.McCall C, McCall W. What Is the Role of Sedating Antidepressants, Antipsychotics, and Anticonvulsants in the Management of Insomnia?. Curr Psychiatry Rep. 2012; 14:494–502.Hirai K, Kita M, Ohta H, et al. Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J Biol Rhythms 2005;2027-37.Zhdanova IV,WurtmanRJ, ReganMM, et al.Melatonin treatment for age-related insomnia. J Clin EndocrinolMetab 2001;86(10)4727–30.Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep a meta-analysis. Sleep Med Rev 2005;941-50Montes LGA, Ontiveros Uribe MP, Cortes Sotres J. Treatment of primary insomnia with melatonin a double-blind, placebo-controlled, cross-over study. J Psychiatry Neurosci 2003;286Singer C, Tractenberg RE, Kaye J, et al.Amulticenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer’s disease. Sleep 2003;26(7)893– 901.Ioachimescu O, El-Solh A. Pharmacotherapy of insomnia. Expert Opin. Pharmacother. 2012; 13(9):1243-1260¨.Liu J, Wang L. Ramelteon in the treatment of chronic insomnia: systematic review and meta-analysis. Int J Clin Pract. 2012; 66(9): 867–873.Pandi-Perumal S, Warren D, Verster J, Srinivasan V, Brown G, Cardinali D et al. Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications. Journal of Central Nervous System Disease 2011;3:51–65.Demyttenaere K. Agomelatine a narrative review. Eur Neuropsychopharmacol. 2011;21(4) S703-9.Leproult R, Van Onderbergen A, L’Hermite-Baleriaux M, et al. Phase-shifts of 24-h rhythms of hormonal release and body temperatura following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol 2005;63:298-304.Zisapel N. Drugs for insomnia. Expert Opin. Emerging Drugs [Early Online]. DOI: 10.1517/14728214.2012.690735.Santos MS, Ferreira F, Cunha AP, et al. Synaptosomal GABA release as influenced by valerian root extract-involvement of the GABA carrier. Arch Int Pharmacodyn Ther 1994;327:220–31.Dietz BM, Mahady GB, Pauli GF, et al. Valerian extract and valerenic acid are partial agonist of the 5 HT [5a] receptors in vitro. Brain Res 2005;138:191–7.Schumacher B, Scholle S, Holzl J, et al. Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A [1] adenosine receptors. J Nat Prod 2002;65:1479–85.Leach M, Page A. Herbal medicine for insomnia: A systematic review and metaanalysis. Sleep Medicine Reviews. 2015; 24: 1-12.Horoszok L, Baleeiro T, D’Aniello F, Gropper S, Santos B, Guglietta A et al. A single-dose, randomized, double-blind, double dummy, placebo and positivecontrolled, five-way cross-over study to assess the pharmacodynamic effects of lorediplon in a phase advance model of insomnia in healthy Caucasian adult male subjects. Hum. Psychopharmacol Clin Exp. 2014; 29: 266–273.Walsh J, Thacker S, Knowles L, Tasker T, Hunneyball I. The partial positive allosteric GABAA receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients. Sleep Medicine. 2009; 10: 859–864.Walsh J, Salkeld L, Knowles L, Tasker T, Hunneyball I. Treatment of elderly primary insomnia patients with EVT 201 improves sleep initiation, sleep maintenance, and daytime sleepiness. Sleep Medicine. 2010;11:23–30.Hoever P, Hay J, Rad M, Cavallaro M, Van Gerven J, Dingemanse J. Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Dose Almorexant, an Orexin Receptor Antagonist, in Healthy Elderly Subjects. J Clin Psychopharmacol. 2013;33(3): 363-370 .Neubauer D. Almorexant, a dual orexin receptor antagonist for the treatment of insomnia. Curr Opin Investig Drugs. 2010 Jan;11(1):101-10.Connor K, Mahoney E, Jackson S, Hutzelmann J, Zhao X, Jia N et al. A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia. International Journal of Neuropsychopharmacology. 2016; 1–10.Zisapel N. Current Phase II investigational therapies for insomnia. Expert Opin. Investig. Drugs. 2014; 24(4): 1-11.Ma Y, Dong M, Mita C, Sun S, Peng CK, Yang A. Publication analysis on insomnia: how much has been done in the past two decades?. Sleep Medicine. 2015;16:820–826.Nissen C, Frase L, Hajak G, Wetter TC. Hypnotika – Stand der Forschung. Nervenarzt. 2014; 85(1):67–76.Lie J, Tu K, Shen D, Wong B. Pharmacological Treatment of Insomnia. P&T. 2015; 40 (11):759-771.Nunes ML, Bruni O. Insomnia in childhood and adolescence: clinical aspects, diagnosis, and therapeuticapproach. J Pediatr (Rio J). 2015;91:S26-35.Meltzer L, Mindell J. Systematic Review and Meta-Analysis of Behavioral Interventions for Pediatric Insomnia. Journal of Pediatric Psychology. 2014; 39(8):932–948.Glass J, Lanctôt KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331:1169-73.Krystal AD. A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: The empirical basis for U.S. clinical practice. Sleep Medicine Reviews. 2009;13: 265–274.Stremler R, Hodnett E, Lee K, et al. A behavioral-educational intervention to promote maternal and infant sleep: a pilot randomized, controlled trial. Sleep 2006;29:1609-15.Okun M, Ebert R, Saini B. A review of sleep-promoting medications used in pregnancy. Am J Obstet Gynecol. 2015; 428-441.Wikner BN, Kallen B. Are hypnotic benzodiazepine receptor agonists teratogenic in humans? J Clin Psychopharmacol 2011;31:356-9.Eros E, Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A populationbased case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolum and clonazepamtreatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 2002;101147-54.Reis M, Kallen B. Combined use of selective serotonin reuptake inhibitors and sedativehypnotics during pregnancy risk of relatively severe congenital malformations or cardiac defects a register study. BMJ Open 2013;3.Gilboa SM, Strickland MJ, Olshan AF, Werler MM, Correa A. Use of antihistamine medications during early pregnancy and isolated major malformations. Birth Defects Res A Clin Mol Teratol 2009;85137-50.Gámez M, Irala C. Selección de benzodiazepinas. Bases para su utilización en el hospital. Farm Hosp 1996; 21 (2): 117-122.Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena N. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ 2012;345:e8343Fabre Jr LF, Brachfeld J, Meyer LR, Slowe IA, Calvo R, Metzler C. Multiclinic double-blind comparison of triazolam (Halcion) and placebo administered for 14 consecutive nights in outpatients with insomnia. J Clin Psychiatry 1978;39(8)679–82.Scharf MB, Sachais BA. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry. 1990;51 (suppl):7-13.Ware JC, Pittard JT. Increased Deep sleep after trazodone use: a dobleblind placebo-controlled study in healthy Young adults. J Clin Psychiatry. 1990;51(cuppl):18-22.Winokur A, Sateia MJ, Hayes JB, Bayles-Dazet W, MacDonald MM. Effects of mirtazapine on sleep architecture in patients with major depression: a pilot study. Biol Psychiatry. 1998; 43(8):106-7.Ruigt GS, Kemp B, Groenhout CM, Kamphuisen HA. Effect of the antidepressant Org 3770 on human sleep. Eur J Clin Pharmacol. 1990;38:551-4.Elie R, Ruther E, Farr I, Emilien G, Salinas E. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. J Clin Psychiatry 1999;60(8):536–44.Walsh JK, Vogel GW, Scharf M, Erman M, William Erwin C, Schweitzer PK, et al. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 2000;1(1):41–9.Perlis ML, McCall WV, Krystal AD, Walsh JK. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry 2004;65(8):1128–37.Scharf MB, Roth T, Vogel GW, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994;55(5):192–9.Walsh JK, Roth T, Randazzo A, Erman M, Jamieson A, Scharf M, et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 2000;23(8):1087–96.Glass J, Lanctôt KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005;331:1169-73.Scharf M, Erman M, Rosenberg R, et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 2005;28(6): 720–7.Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999;281(11):991–9.Ancoli-Israel S, Walsh JK, Mangano RM, Fujimori M. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Prim Care Companion J Clin Psychiatry 1999;1(4):114–20.Hedner J, Yaeche R, Emilien G, Farr I, Salinas E. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group. Int J Geriatr Psychiatry 2000;15(8):704–12.Roth T, Seiden D, Wang-Weigand S, Zhang J. A 2-night, 3-period, crossover study of ramelteon’s efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007;23(5):1005–14.Dundar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, et al. Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. Health Technol Assess 2004;8(24).Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M et al. The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Metaanalysis of RCTs. Society of General Internal Medicine 2007;22:1335–1350.Contreras A. Insomnio: generalidades y alternativas terapéuticas de última generación. Rev. Med. Clin. CONDES. 2013; 24(3) 433-441.Fernández O, López F, Villarín A, Tena J, Morales M, Rodriguez C. Tratamiento del insomnio. Boletin Farmacoterapeutico de Castilla La Mancha. 2010; 11(1)Barros J. Tranquilizantes benzodiazepínicos: ¿instrumento de cura o de medicalización?. AIS-Bol. 1999; 14(16): 33-37Campo M, Albiñama M, Ferrari J, Herreros A. Utilización del hidrato de cloral en pediatría. Usos clínicos, preparaciones calénicas y experiencia en un hospital. Farm Hosp. 1999; 23(3):170-175.Sierra JC, Martín J, Poveda J. Efectos de una dosis de diazepam sobre el estado emocional en una muestra no clínica. Psicología y Salud. 2003; 13(1):103-110.Jufe GS. Nuevos hipnóticos: perspectivas desde la fisiología del sueño. Rev. Arg. de Psiquiat. 2007;18:294-299.López F, Fernández O, Maraque MA, Fernández L. Abordaje terapéutico del insomnio. Semergen. 2012;38(4):233-240.Buysse D. Insomnia. JAMA. 2013; 309(7): 706-716.Morin Charles M., Benca Ruth. Chronic insomnia. Seminar. Lancet 2012; 379:1129–41.Durand –Arias So, Rojas-Avila Cynthia, Jimenez-Genchi Alejandro. Evaluación clínica de los síntomas relacionados con el dormir. Psiquis. (Mexico), 2011; 20 (1):17-22Contreras A. Sueño a lo largo de la vida y sus implicaciones en salud. Rev. Med. Clin. CONDES. 2013; 24(3) 341-349.Aguirre-Navarrete R. Bases anatómicas y fisiológicas del sueño. Rev. Ecuat. Neurol. 2007;15 (2).Ocampo-Garcés A, Castro J, Espinoza D. Mecanismos neuronales en el control del dormir. Rev Hosp Clin Univ Chile. 2012; 23: 5-12.Talero-Gutiérrez C, Durán-Torres F, Pérez I. Sueño: características generales. Patrones fisiológicos y fisiopatológicos en la adolescencia. Rev Cienc Salud. 2013;11(3):333-48Cano J, Garcìa J. Insomnio: enfoque diagnòstico y terapéutico. IATREIA. 2005;18(1): 60-70.Grupo de Trabajo de la Guía de Práctica Clínica para el Manejode Pacientes con Insomnio en Atención Primaria. Guía de Prác-tica Clínica para el Manejo de Pacientes con Insomnio enAtención Primaria. Plan de Calidad para el Sistema Nacionalde Salud del Ministerio de Sanidad y Política Social. Unidadde Evaluación de Tecnologías Sanitarias. Agencia Laín Entralgo.Comunidad de Madrid. Ed. Ministerio de Ciencia e Innovación,Ciempozuelos (Madrid) 2009. Guías de Práctica Clínica en el SNS:UETS N.◦2007/5-1.Escobar F, Echeverry J, Lorenzana P. Tratamiento farmacológico del insomnio 2ª parte. Rev Fac Med UN Col. 2001; 49(3): 147-154.Fernández M, Masa R, Palacios L, Sancho P, Calbó C, Flores G. Effectiveness of Valerian on insomnia: A meta-analysis of randomized placebo-controlled trials. Sleep Medicine. 2010; 11: 505–511.Sukys L, dos Santos W, Tufik S, Poyares D. Novos sedativos hipnóticos. Revista Brasileira de Psiquiatria. 2010;32(3): 288-293.Adán MA, Acín MT, Díaz J, Alejandre G, Pérez J. ¿Cómo utilizamos los hipnóticos en atención primaria?. Semergen. 2010;36(7):372–376.LICENSElicense.txtlicense.txttext/plain; charset=utf-8368https://bonga.unisimon.edu.co/bitstreams/9aac430c-2045-4e17-bd12-2384ac7185da/download3fdc7b41651299350522650338f5754dMD5220.500.12442/1916oai:bonga.unisimon.edu.co:20.500.12442/19162024-08-14 21:53:33.544metadata.onlyhttps://bonga.unisimon.edu.coRepositorio Digital Universidad Simón Bolívarrepositorio.digital@unisimon.edu.coPGEgcmVsPSJsaWNlbnNlIiBocmVmPSJodHRwOi8vY3JlYXRpdmVjb21tb25zLm9yZy9saWNlbnNlcy9ieS1uYy80LjAvIj48aW1nIGFsdD0iTGljZW5jaWEgQ3JlYXRpdmUgQ29tbW9ucyIgc3R5bGU9ImJvcmRlci13aWR0aDowIiBzcmM9Imh0dHBzOi8vaS5jcmVhdGl2ZWNvbW1vbnMub3JnL2wvYnktbmMvNC4wLzg4eDMxLnBuZyIgLz48L2E+PGJyLz5Fc3RhIG9icmEgZXN0w6EgYmFqbyB1bmEgPGEgcmVsPSJsaWNlbnNlIiBocmVmPSJodHRwOi8vY3JlYXRpdmVjb21tb25zLm9yZy9saWNlbnNlcy9ieS1uYy80LjAvIj5MaWNlbmNpYSBDcmVhdGl2ZSBDb21tb25zIEF0cmlidWNpw7NuLU5vQ29tZXJjaWFsIDQuMCBJbnRlcm5hY2lvbmFsPC9hPi4= |